Company Details
  • Conbott Pharmtech Co.,Ltd.

  •  [Zhejiang,China]
  • Business Type:Manufacturer
  • Main Mark: Africa , Americas , Asia , Caribbean , East Europe , Europe , Middle East , North Europe , Oceania , Other Markets , West Europe , Worldwide
  • Exporter:71% - 80%
  • Certs:COS, ISO9001, ISO14010, FDA
  • Description:162635-04-3,CAS 162635-04-3,CAS NO 162635-04-3
Conbott Pharmtech Co.,Ltd. 162635-04-3,CAS 162635-04-3,CAS NO 162635-04-3
Home > Products > Inhibitors > MTOR Inhibitor > MTOR Inhibitor Temsirolimus CAS 162635-04-3
  • Title
  • All
Online Service
http://www.conbottpharm.comScan to visit

MTOR Inhibitor Temsirolimus CAS 162635-04-3

Share to:  
    Min. Order: 1 Gram
    Delivery Time: 10 Days

Basic Info

Model No.: 162635-04-3

Additional Info

Packaging: As required

Productivity: Customized

Brand: Conbottpharm

Transportation: Air

Place of Origin: China

Supply Ability: Commercial

Certificate: Documents Support

Product Description

Temsirolimus CAS 162635-04-3 is also called CCI-779, NSC 683864, Torisel and Sirolimus which is a specific inhibitor of mTOR with IC50 of 1.76 μM. It can soluble to 100 mM in DMSO and to 100 mM in ethanol. The Temsirolimus CAS NO 162635-04-3, supplied by us, is high purity, less impurity, premium quality and safe formulation. Temsirolimus (CCI-779) 162635-04-3 is also an intravenous drug for the treatment of renal cell carcinoma (RCC). We can arrange fast delivery and offer best service.

Thera. Category: Anti angiogenic

Cas No.: 162635-04-3

Synonym: TEMSIROLIMUS;CCL-779;Rapamycin 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate;42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin;C15182;TeMsiroliMus (CCI-779, Torisel);rapaMycin 42-ester with 3-hydroxy-2-(hydroxyMethyl)-2-Methylpropionic acid;TeMsiroliMus (Torisel)


Molecular Formula: C56H87NO16

Molecular Weight: 1030.29

Assay: ≥99.%

Packing: Export worthy packing

lMaterial Safety Data Sheet: Available on request

Usage:Temsirolimus (CCI-779) is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA) in late May 2007,[2] and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative and prodrug of sirolimus.

Looking for ideal 162635-04-3 Manufacturer & supplier ? We have a wide selection at great prices to help you get creative. All the CAS 162635-04-3 are quality guaranteed. We are China Origin Factory of CAS NO 162635-04-3. If you have any question, please feel free to contact us.

Product Categories : Inhibitors > MTOR Inhibitor

Product Images
  • MTOR Inhibitor Temsirolimus CAS 162635-04-3
Email to this supplier
  • *Subject:
  • *Messages:
    Your message must be between 20-8000 characters
Copyright © 2020 Conbott Pharmtech Co.,Ltd. All rights reserved.
Communicate with Supplier?Supplier
Tommy Mr. Tommy
What can I do for you?